Skip to main content
SpringerLink
Log in

Arteriosklerose und Durchblutungsstörungen

  • Chapter
Pharmakotherapie

Part of the book series: Springer-Lehrbuch ((SLB))

  • 284 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Weiterführende Literatur

  • Adams HP, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ (2003) Guidelines for the early management of patients with ischemic stroke. Stroke 34: 1056–1083

    Article  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Primär-und Sekundärprävention des ischämischen Insults. AVP-Sonderheft, 1. Auflage, Juli 1999

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie der PAVK. AVP-Sonderheft 7, 1. Auflage, August 1997

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft: Empfehlungen zur Therapie von Fettstoffwechselstörungen. AVP-Sonderheft, 2. Auflage, Juli 1999

    Google Scholar 

  • Bachand RT, Dubourg AY (1990) A review of long-term safety data with buflomedil. J. Int. Med. Res. 18: 245–252

    PubMed  CAS  Google Scholar 

  • Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE, Bortey EB, Forbes WP (1999) A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch. Int. Med. 159:2041–2050

    Article  CAS  Google Scholar 

  • Belch JJ, Ho M (1996) Pharmacotherapy of Raynaud’s phenomenon. Drugs 52:682–695

    Article  PubMed  CAS  Google Scholar 

  • CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  Google Scholar 

  • Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL (2002) Anticoagulants and antiplatelet agents in acute ischemic stroke. Stroke 33: 1934–1942

    Article  PubMed  CAS  Google Scholar 

  • Davinroy M, Mosnier M (1993) Évaluation clinique en double-insu du nafti-drofuryl dans le phénomène de raynaud. Sem. Hôp. Paris 69: 1322–1326

    Google Scholar 

  • De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 16: 779–785

    Google Scholar 

  • Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646–2655

    Article  PubMed  CAS  Google Scholar 

  • Girolami B, Bernardi E, Prins MH, Wouter ten Cate J, Hettiarachchi R, Prandoni P, Girolami A, Büller HR (1999) Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl — a meta-analysis. Arch. Int. Med. 159: 337–345

    Article  CAS  Google Scholar 

  • Gohlke H, Kübler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G; Deutsche Gesellschaft für Kardiologie-Herz-und Kreislaufforschung (2003) Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z. Kardiol. 92: 522–524

    CAS  Google Scholar 

  • Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 23–33

    Article  Google Scholar 

  • Hirsh J, Hoak J (1996) Management of deep vein thrombosis and pulmonary embolism. Circulation 93: 2212–2245

    PubMed  CAS  Google Scholar 

  • Hodis HN, Mack WJ, Azen SP et al., Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 349: 535–45

    Article  PubMed  CAS  Google Scholar 

  • International Stroke Trial Collaborative Group (1997) The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569–1581

    Article  Google Scholar 

  • Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K (2003) American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562–1566

    Article  PubMed  Google Scholar 

  • Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106: 2747–2757

    Article  PubMed  Google Scholar 

  • Kwiterovich PO (1998) State-of-the-art update and review: clinical trials of lipid-lowering agents. Am. J. Cardiol. 82: 3U–17U

    Article  PubMed  CAS  Google Scholar 

  • Leitlinien der Deutschen Gesellschaft für Phlebologie (1998) Leitlinie zur Diagnostik und Therapie der Thrombophlebitis superficialis. Phlebologie 27:58–59

    Google Scholar 

  • Leitlinien der Deutschen Gesellschaft für Phlebologie (1998) Leitlinie zur Diagnostik und Therapie der tiefen Bein-/Beckenvenenthrombose. Phlebologie 27: 84–88

    Google Scholar 

  • Marchioli R, Barzi F, Bomba E et al., GISSI-Prevenzione Investigators (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105: 1897–1903

    Article  PubMed  CAS  Google Scholar 

  • Richmond R, Zwar N (2003) Review of bupropion for smoking cessation. Drug Alcohol Rev. 22: 203–220

    Article  PubMed  Google Scholar 

  • Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347: 1557–1565

    Article  PubMed  CAS  Google Scholar 

  • Ross R (1999) Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340:115–126

    Article  PubMed  CAS  Google Scholar 

  • Sachdev GP, Ohlrogge KD, Johnson CL (1999) Review of the fifth american college of chest physicians consensus conference on antithrombotic therapy: outpatient management for adults. Am. J. Health-Syst. Pharm. 56:1505–1514

    PubMed  CAS  Google Scholar 

  • Schwartz GG, Olsson AG, Ezekowitz MD, et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718

    Article  PubMed  CAS  Google Scholar 

  • Sever PS, Dahlöf B, Poulter NR et al., for the ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158

    Article  PubMed  CAS  Google Scholar 

  • Stavenow L, Kjellström T (1999) Influence of serum triglyceride levels on the risk for myocardial infarction in 12510 middle aged males: interaction with serum cholesterol. Atherosclerosis 147: 243–247

    Article  PubMed  CAS  Google Scholar 

  • Zusman RM, Chesebro JH, Comerota A, Hartmann JR, Massin EK, Raps E, Wolf PA (1999) Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection. Clin. Cardiol. 22: 559–573

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie Fakultät fü Klinische Medizin Mannheim, Ruprecht-Karls-Universtät Heidelberg, Maybachstraße 14–16, 68169, Mannheim

    PD Dr. med. K. Witte

  2. Hegau-Klinikum, Medizinische Klinik I, Birchowstraße 10, 78221, Singen

    PD Dr. med. C. Haller

  3. Medizinische Universitätsklinik und Poliklinik, Bergheimer Straße 58, 69115, Heidelberg

    PD Dr. med. C. Haller

Authors
  1. PD Dr. med. K. Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. med. C. Haller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Heidelberg

About this chapter

Cite this chapter

Witte, K., Haller, C. (2004). Arteriosklerose und Durchblutungsstörungen. In: Pharmakotherapie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-35149-3_19

Download citation

  • DOI: https://doi.org/10.1007/3-540-35149-3_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20414-5

  • Online ISBN: 978-3-540-35149-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation